Intercept Pharmaceuticals (NASDAQ:ICPT) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Thursday, December 7th.
Other equities research analysts have also issued reports about the stock. Citigroup reiterated a “neutral” rating and set a $150.00 price target on shares of Intercept Pharmaceuticals in a research note on Tuesday, September 19th. UBS Group lowered shares of Intercept Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, September 22nd. Cowen reiterated a “buy” rating and set a $112.00 price target on shares of Intercept Pharmaceuticals in a research note on Wednesday, November 1st. Oppenheimer restated a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Tuesday, October 24th. Finally, Needham & Company LLC restated a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Wednesday, November 1st. Four investment analysts have rated the stock with a sell rating, ten have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $141.58.
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded down $2.07 during trading hours on Thursday, reaching $56.35. 1,911,529 shares of the company traded hands, compared to its average volume of 617,379. Intercept Pharmaceuticals has a 12-month low of $54.98 and a 12-month high of $135.59. The company has a debt-to-equity ratio of 3.15, a current ratio of 5.95 and a quick ratio of 5.95. The firm has a market cap of $1,410.00, a price-to-earnings ratio of -3.81 and a beta of -2.08.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 176.51%. The firm had revenue of $41.33 million for the quarter, compared to analyst estimates of $36.95 million. During the same period last year, the business earned ($3.59) EPS. Intercept Pharmaceuticals’s revenue for the quarter was up 697.9% compared to the same quarter last year. research analysts anticipate that Intercept Pharmaceuticals will post -13.35 EPS for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in the stock. FMR LLC boosted its holdings in Intercept Pharmaceuticals by 0.7% during the second quarter. FMR LLC now owns 3,750,678 shares of the biopharmaceutical company’s stock worth $454,094,000 after buying an additional 25,958 shares in the last quarter. Carmignac Gestion boosted its holdings in Intercept Pharmaceuticals by 0.4% during the second quarter. Carmignac Gestion now owns 2,035,592 shares of the biopharmaceutical company’s stock worth $246,449,000 after buying an additional 7,400 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Intercept Pharmaceuticals by 4.5% during the second quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock worth $160,797,000 after buying an additional 57,149 shares in the last quarter. Senvest Management LLC purchased a new stake in Intercept Pharmaceuticals during the third quarter worth about $33,883,000. Finally, First Trust Advisors LP boosted its holdings in Intercept Pharmaceuticals by 4.5% during the third quarter. First Trust Advisors LP now owns 300,455 shares of the biopharmaceutical company’s stock worth $17,438,000 after buying an additional 13,044 shares in the last quarter. 73.76% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was first published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.truebluetribune.com/2018/01/03/intercept-pharmaceuticals-icpt-downgraded-to-sell-at-bidaskclub.html.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.